63 related articles for article (PubMed ID: 25803370)
41. Frequency of precancerous changes and cervical cancer recorded in three health centres in tuzla canton in period 2010-2011.
Jahic M; Mulavdic M; Dautbasic F; Fejzic M; Jahic E
Mater Sociomed; 2013 Dec; 25(4):259-61. PubMed ID: 24511270
[TBL] [Abstract][Full Text] [Related]
42. Cervical Smears at Public Health Centres in Eastern Trinidad: Coverage and Follow-up, 2009-2010.
Lynch-George G; Maharaj RG
West Indian Med J; 2014 Jul; 63(6):575-81. PubMed ID: 25803370
[TBL] [Abstract][Full Text] [Related]
43. Assessment of cytologic follow-up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions.
Alanen KW; Elit LM; Molinaro PA; McLachlin CM
Cancer; 1998 Feb; 84(1):5-10. PubMed ID: 9500646
[TBL] [Abstract][Full Text] [Related]
44. Clinical evaluation of follow-up methods and results of atypical glandular cells of undetermined significance (AGUS) detected on cervicovaginal Pap smears.
Kim TJ; Kim HS; Park CT; Park IS; Hong SR; Park JS; Shim JU
Gynecol Oncol; 1999 May; 73(2):292-8. PubMed ID: 10329049
[TBL] [Abstract][Full Text] [Related]
45. Prevalence of Abnormal Pap Smears: A Descriptive Study from a Cancer Center in a Low-Prevalence Community.
Maraqa B; Lataifeh I; Otay L; Badran O; Qutaiba Nouri Y; Issam I; Al Hussaini M
Asian Pac J Cancer Prev; 2017 Nov; 18(11):3117-3121. PubMed ID: 29172288
[TBL] [Abstract][Full Text] [Related]
46. Follow-up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion: a nationwide cohort study.
Sundström K; Lu D; Elfström KM; Wang J; Andrae B; Dillner J; Sparén P
Am J Obstet Gynecol; 2017 Jan; 216(1):48.e1-48.e15. PubMed ID: 27457115
[TBL] [Abstract][Full Text] [Related]
47. The Correlation of Papanicolaou Smears and Clinical Features to Identify the Common Risk Factors for Cervical Cancer: A Retrospective and Descriptive Study from a Tertiary Care Hospital in Trinidad.
Umakanthan S; Bukelo MM; Ghany S; Gay D; Gilkes T; Freeman J; Francis A; Francis K; Gajadhar G; Fraser J
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992281
[No Abstract] [Full Text] [Related]
48. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
Ferlay J; Shin HR; Bray F; Forman D; Mathers C; Parkin DM
Int J Cancer; 2010 Dec; 127(12):2893-917. PubMed ID: 21351269
[TBL] [Abstract][Full Text] [Related]
49. Challenges faced by cervical cancer prevention programs in developing countries: a situational analysis of program organization in Argentina.
Arrossi S; Paolino M; Sankaranarayanan R
Rev Panam Salud Publica; 2010 Oct; 28(4):249-57. PubMed ID: 21152712
[TBL] [Abstract][Full Text] [Related]
50. Perspectives on Pap test follow-up care among rural Appalachian women.
Schoenberg N; Baltisberger J; Bardach S; Dignan M
Women Health; 2010 Sep; 50(6):580-97. PubMed ID: 20981638
[TBL] [Abstract][Full Text] [Related]
51. Cervical cancer assessment in Romania under EUROCHIP-2.
Apostol I; Baban A; Nicula F; Suteu O; Coza D; Amati C; Baili P;
Tumori; 2010; 96(4):545-52. PubMed ID: 20968133
[TBL] [Abstract][Full Text] [Related]
52. [Evaluation of the follow-up of women aged 50-74 years after cervical cytological Ascus abnormalities in cancer screening: adherence to clinical practice guidelines in Isere, France; 1991-2000].
Billette-de-Villemeur A; Poncet F; Garnier A; Marron J; Le Marc'hadour F; Morens A; Rouault-Plantaz V; Ney M; Exbrayat C
Gynecol Obstet Fertil; 2009 Oct; 37(10):787-95. PubMed ID: 19782628
[TBL] [Abstract][Full Text] [Related]
53. Cervical cancer screening programs in Latin America and the Caribbean.
Murillo R; Almonte M; Pereira A; Ferrer E; Gamboa OA; Jerónimo J; Lazcano-Ponce E
Vaccine; 2008 Aug; 26 Suppl 11():L37-48. PubMed ID: 18945401
[TBL] [Abstract][Full Text] [Related]
54. Variations in practice guideline adherence for abnormal cervical cytology in a county healthcare system.
Singhal R; Rubenstein LV; Wang M; Lee ML; Raza A; Holschneider CH
J Gen Intern Med; 2008 May; 23(5):575-80. PubMed ID: 18286344
[TBL] [Abstract][Full Text] [Related]
55. Factors affecting uptake of cervical cancer screening among clinic attendees in Trelawny, Jamaica.
Bessler P; Aung M; Jolly P
Cancer Control; 2007 Oct; 14(4):396-404. PubMed ID: 17914340
[TBL] [Abstract][Full Text] [Related]
56. A participatory assessment to identify strategies for improved cervical cancer prevention and treatment in Bolivia.
Dzuba IG; Calderón R; Bliesner S; Luciani S; Amado F; Jacob M
Rev Panam Salud Publica; 2005 Jul; 18(1):53-63. PubMed ID: 16105327
[No Abstract] [Full Text] [Related]
57. Situation analysis for cervical cancer diagnosis and treatment in east, central and southern African countries.
Chirenje ZM; Rusakaniko S; Kirumbi L; Ngwalle EW; Makuta-Tlebere P; Kaggwa S; Mpanju-Shumbusho W; Makoae L
Bull World Health Organ; 2001; 79(2):127-32. PubMed ID: 11242819
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
